Work

GLP-1 and Intestinal Diseases

Year: 2021
Type: review
Abstract: Accumulating evidence implicates glucagon-like peptide-1 (GLP-1) to have, beyond glucose maintenance, a beneficial role in the gastrointestinal tract. Here, we review emerging data investigating GLP-1 as a novel treatment for intestinal diseases, including inflammatory bowel diseases, short-bowel syndrome, intestinal toxicities and coeliac disease. Possible beneficial mechanisms for these diseases include GLP-1's influence on gastric emptying, its anti-inflammatory properties and its intestinotrophic effect. The current knowledge basis derives from the available GLP-1 agonist treatments in experimental animals and small clinical trials. However, new novel strategies including dual GLP-1/GLP-2 agonists are also in development for the treatment of intestinal diseases.
Source: Biomedicines
Language: English
Field: Medicine
Open Access status: gold
Estimated APC paid: $2,160
OpenAlex ID: W3143157476
FWCI: 1.382
Cites: 96
Cited by: 72
Related to: 10